Refine by
Destiny Pharma Clinically Studied Equipment & Supplies
3 equipment items found
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
A Phase 2b clinical study, which was a multi-centre, randomized, placebo-controlled study of XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) completed recruitment at the end of 2020 and top-line results were reported in Q1 2021, as ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
Background to the NTCD-M3 Clostridioides difficile Programme. NTCD-M3 was developed by GI infection physician, Professor Dale Gerding, who is a world-leading specialist in C. difficile, with more than 400 peer-reviewed journal publications, book chapters and review articles in the area. NTCD-M3 has successfully completed Phase 1 and Phase 2b trials with NTCD-M3. The Phase 1 study demonstrated a ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action. Destiny Pharma’s XF platform has advantages over traditional antibiotics. ...